Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) FCF Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed FCF Margin for 4 consecutive years, with 32.15% as the latest value for Q1 2025.

  • Quarterly FCF Margin rose 356867.0% to 32.15% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 95.95% through Dec 2025, up 158749.0% year-over-year, with the annual reading at 95.95% for FY2025, 157788.0% up from the prior year.
  • FCF Margin for Q1 2025 was 32.15% at Century Therapeutics, up from 580.47% in the prior quarter.
  • The five-year high for FCF Margin was 7840.93% in Q1 2022, with the low at 28046.46% in Q2 2023.
  • Average FCF Margin over 4 years is 4943.69%, with a median of 3579.38% recorded in 2024.
  • The sharpest move saw FCF Margin plummeted -2646530bps in 2023, then skyrocketed 2446709bps in 2024.
  • Over 4 years, FCF Margin stood at 5599.81% in 2022, then tumbled by -81bps to 10152.99% in 2023, then skyrocketed by 94bps to 580.47% in 2024, then soared by 94bps to 32.15% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 32.15%, 580.47%, and 3581.8% for Q1 2025, Q4 2024, and Q3 2024 respectively.